Suzano Shares Face Pivotal Month of Catalysts

February presents a series of critical events for Suzano, the global pulp producer, that are set to shape investor sentiment. The company's upcoming earnings release and a key regulatory review for a major joint venture will provide significant direction for the stock in the near term.

From a strategic standpoint, Suzano is planning a notable reduction in its capital expenditure (Capex) for the current year. The firm has budgeted 10.9 billion Brazilian Real for investments in 2026, marking a substantial decrease from the estimated 13.3 billion Real allocated for 2025. This adjustment is primarily attributed to lower projected forest maintenance costs.

Concurrently, the broader pulp market environment appears to be shifting in favor of producers. Industry analyses point toward a potential tightening of supply throughout 2026 and 2027. Should capacity utilization reach a critical threshold, pricing power for major players like Suzano could strengthen. However, a crucial variable remains the capacity expansion and export strategy of China, which continues to exert influence on global price dynamics.

Earnings Spotlight and Regulatory Scrutiny

The immediate focus for the market will be the company's financial performance. Suzano is scheduled to release its fourth-quarter 2025 results after market close on February 10, 2026. A detailed webcast discussion with management will follow on February 11, 2026. These events are viewed as a key barometer of the corporation's recent financial health.

Should investors sell immediately? Or is it worth buying Suzano?

In parallel, a significant corporate move is undergoing regulatory examination. The planned majority stake acquisition in Kimberly-Clark's international tissue business, agreed upon in June 2025, is now under review by the UK's Competition and Markets Authority (CMA). The regulator has initiated a consultation phase, with market participants invited to submit comments until February 20, 2026. Following this period, the CMA will decide whether to launch a formal in-depth investigation, a necessary step before the deal can receive final clearance.

Key Dates for Investors:

• February 10, 2026: Q4 2025 earnings release (post-market).
• February 11, 2026: Quarterly results webcast.
• February 20, 2026: Deadline for comments to the UK CMA.

The outcome of these weeks will be decisive for the equity's short-term trajectory. The conclusion of the CMA's consultation and the fresh financial data will clarify whether Suzano can advance its strategic goals amidst regulatory reviews and complex global trade flows. Ultimately, the materialization of the forecasted market supply crunch will be a determining factor in the company's ability to deliver sustainable margin improvement this year.